title: Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama.
abstract: A standardized elderberry extract, Sambucol (SAM), reduced hemagglutination and inhibited replication of human influenza viruses type A/Shangdong 9/93 (H3N2), A/Beijing 32/92 (H3N2), A/Texas 36/91 (H1N1), A/Singapore 6/86 (H1N1), type B/Panama 45/90, B/Yamagata 16/88, B/Ann Arbor 1/86, and of animal strains from Northern European swine and turkeys, A/Sw/Ger 2/81, A/Tur/Ger 3/91, and A/Sw/Ger 8533/91 in Madin-Darby canine kidney cells. A placebo-controlled, double blind study was carried out on a group of individuals living in an agricultural community (kibbutz) during an outbreak of influenza B/Panama in 1993. Fever, feeling of improvement, and complete cure were recorded during 6 days. Sera obtained in the acute and convalescent phases were tested for the presence of antibodies to influenza A, B, respiratory syncytial, and adenoviruses. Convalescent phase serologies showed higher mean and mean geometric hemagglutination inhibition (HI) titers to influenza B in the group treated with SAM than in the control group. A significant improvement of the symptoms, including fever, was seen in 93.3% of the cases in the SAM-treated group within 2 days, whereas in the control group 91.7% of the patients showed an improvement within 6 days (p < 0.001). A complete cure was achieved within 2 to 3 days in nearly 90% of the SAM-treated group and within at least 6 days in the placebo group (p < 0.001). No satisfactory medication to cure influenza type A and B is available. Considering the efficacy of the extract in vitro on all strains of influenza virus tested, the clinical results, its low cost, and absence of side-effects, this preparation could offer a possibility for safe treatment for influenza A and B.
authors.affiliation: Department of Virology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
authors.forename: Z
authors.initials: Z
authors.lastname: Zakay-Rones
authors.forename: N
authors.initials: N
authors.lastname: Varsano
authors.forename: M
authors.initials: M
authors.lastname: Zlotnik
authors.forename: O
authors.initials: O
authors.lastname: Manor
authors.forename: L
authors.initials: L
authors.lastname: Regev
authors.forename: M
authors.initials: M
authors.lastname: Schlesinger
authors.forename: M
authors.initials: M
authors.lastname: Mumcuoglu
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D004196:Disease Outbreaks; D004285:Dogs; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D009980:Influenza A virus / Q000145:classification / Q000276:immunology; D009981:Influenza B virus / Q000145:classification / Q000276:immunology; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology*; D037102:Lectins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D037121:Plant Lectins; D054788:Ribosome Inactivating Proteins; D012703:Serotyping
chemical_list: D000914:Antibodies, Viral; D037102:Lectins; D010936:Plant Extracts; D037121:Plant Lectins; C050600:Sambucus nigra lectins; D054788:Ribosome Inactivating Proteins